Menopause

Invigorating homeopathic oral spray for the temporary relief of mood swings, hot flashes, irritability & low libido associated with hormonal menopause.†

†These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

There are no additional details available for this product.

Sources

Menopause Manufacturers

Biovea

Menopause | Biovea

Adults only. Spray twice under the tongue 3 times per day.

No Recall
New Sun Inc.

Menopause | New Sun Inc.

Directions: Before initial dose depress pump 4-5 times or until primed and spray 1 dose directly in mouth 4 to 6 times daily until symptoms improve.
Adult Dose: 3 Pump Sprays
Child's Dose (2-12): 2 Pump Sprays
Infants - 2 yrs. 1 Pump Spray

No Recall
Apotheca Company

Menopause | Clinical Solutions Wholesale, Llc

Ethambutol hydrochloride should not be used alone, in initial treatment or in retreatment. Ethambutol hydrochloride should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.
Ethambutol hydrochloride is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.
Initial Treatment
In patients who have not received previous antituberculous therapy, administer ethambutol hydrochloride 15 mg/ kg (7 mg/lb) of body weight, as a single oral dose once every 24 hours. In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose.
Retreatment
In patients who have received previous antituberculous therapy, administer ethambutol hydrochloride 25 mg/kg (11 mg/lb) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in-vitro tests. Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of ethambutol hydrochloride administration, decrease the dose to 15 mg/kg (7 mg/lb) of body weight, and administer as a single oral dose once every 24 hours.
During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.
See Table for easy selection of proper weight-dose tablet(s).
Weight-Dose Table 15 mg/kg (7 mg/lb) Schedule Weight Range Daily Dose
Pounds
Kilograms
-----------------
In mg
Under 85 lbs.
Under 37 kg
-----------------
500
85 – 94.5
37 – 43
-----------------
600
95 – 109.5
43 – 50
-----------------
700
110 – 124.5
50 – 57
-----------------
800
125 – 139.5
57 – 64
-----------------
900
140 – 154.5
64 – 71
-----------------
1000
155 – 169.5
71 – 79
-----------------
1100
170 – 184.5
79 – 84
-----------------
1200
185 – 199.5
84 – 90
-----------------
1300
200 – 214.5
90 – 97
-----------------
1400
215 and Over
Over 97
-----------------
1500
25 mg/kg (11 mg/lb) Schedule
Under 85 lbs.
Under 38 kg
-----------------
900
85 – 92.5
38 – 42
-----------------
1000
93 – 101.5
42 – 45.5
-----------------
1100
102 – 109.5
45.5 – 50
-----------------
1200
110 – 118.5
50 – 54
-----------------
1300
119 – 128.5
54 – 58
-----------------
1400
129 – 136.5
58 – 62
-----------------
1500
137 – 146.5
62 – 67
-----------------
1600
147 – 155.5
67 – 71
-----------------
1700
156 – 164.5
71 – 75
-----------------
1800
165 – 173.5
75 – 79
-----------------
1900
174 – 182.5
79 – 83
-----------------
2000
183 – 191.5
83 – 87
-----------------
2100
192 – 199.5
87 – 91
-----------------
2200
200 – 209.5
91 – 95
-----------------
2300
210 – 218.5
95 – 99
-----------------
2400
219 and Over
Over 99
-----------------
2500

No Recall
Natural Health Supply

Menopause | Natural Health Supply

Take at onset of symptoms. Repeat every 2 hours or as needed until relieved. If condition persists or worsens discontinue use and consult a practitioner.
Adults: dissolve 5-10 pellets in 1 oz. of filtered water or take dry by mouth. Children and infants: 1-5 pellets.

No Recall
White Manufacturing Inc. Dba Micro-west

Menopause | White Manufacturing Inc. Dba Micro-west

DIRECTIONS: ORALLY 6 DROPS, 4 TIMES A DAY

No Recall
Hyland’s

Menopause | Hyland's

Adults
Dissolve 2-3 tablets under tongue every 4 hours or as needed.

No Recall
Bioactive Nutritional, Inc.

Menopause | Proficient Rx Lp

There is no fixed dosage regimen for the management of diabetes mellitus with glipizide or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.
Short-term administration of glipizide may be sufficient during periods of transient loss of control in patients usually controlled well on diet.
In general, glipizide should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.
Initial Dose
The recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg.
Titration
Dosage adjustments should ordinarily be in increments of 2.5 to 5 mg, as determined by blood glucose response. At least several days should elapse between titration steps. If response to a single dose is not satisfactory, dividing that dose may prove effective. The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content. The maximum recommended total daily dose is 40 mg.
Maintenance
Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided. Total daily doses above 30 mg have been safely given on a b.i.d. basis to long-term patients.
In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypo glycemic reactions (see PRECAUTIONS section).
Patients Receiving Insulin
As with other sulfonylurea-class hypoglycemics, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on glipizide. When transferring patients from insulin to glipizide, the following general guidelines should be considered:
• For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages. Several days should elapse between glipizide titration steps. • For patients whose daily insulin requirement is greater than 20 units, the insulin dose should be reduced by 50% and glipizide therapy may begin at usual dosages. Subsequent reductions in insulin dosage should depend on individual patient response. Several days should elapse between glipizide titration steps.
During the insulin withdrawal period, the patient should test urine samples for sugar and ketone bodies at least three times daily. Patients should be instructed to contact the prescriber immediately if these tests are abnormal. In some cases, especially when patient has been receiving greater than 40 units of insulin daily, it may be advisable to consider hospitalization during the transition period.
Patients Receiving Other Oral Hypoglycemic Agents
As with other sulfonylurea-class hypoglycemics, no transition period is necessary when transferring patients to glipizide. Patients should be observed carefully (1 to 2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to glipizide due to potential overlapping of drug effect.
When colesevelam is coadministered with glipizide ER, maximum plasma concentration and total exposure to glipizide is reduced. Therefore, glipizide should be administered at least 4 hours prior to colesevelam.

No Recall
Newton Laboratories, Inc.

Menopause | Newton Laboratories, Inc.

Directions: ORAL USE ONLY - SHAKE WELL. Adults, take 6 drops orally one to four times daily or as directed by a healthcare professional. Sensitive persons begin with 1 drop and gradually increase to full dose.

No Recall
Newton Laboratories, Inc.

Menopause | Newton Laboratories, Inc.

Directions: ORAL USE ONLY - SHAKE WELL. Adults, take 6 drops orally one to four times daily or as directed by a healthcare professional.

No Recall
Newton Laboratories, Inc.

Menopause | Newton Laboratories, Inc.

Directions: Adults, take 6 pellets orally one to four times daily or as directed by a healthcare professional. Sensitive persons begin with 1 pellet and gradually increase to full dose.

No Recall
Newton Laboratories, Inc.

Menopause | Newton Laboratories, Inc.

Directions: Adults, take 6 pellets orally one to four times daily or as directed by a healthcare professional.

No Recall
Liddell Laboratories, Inc.

Menopause | Amorepacific

Apply liberally 15 minutes before sun exposure. Reapply at least every 2 hours. Use a water-resistant sunscreen if swimming or sweating. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: Limit time in the sun, especially from 10 a.m. - 2 p.m. Wear long-sleeved shirts, pants, hats, and sunglasses. Children under 6 months of age: Ask a doctor

No Recall